Prostate Cancer P D:前列腺癌中质子放射治疗与光子放射治疗比较

2019-04-23 AlexYang MedSci原创

放射技术的进展改变了局部前列腺癌患者的治疗选择。三维适形放射治疗和可调节强度放射治疗(IMRT)使得医生可以避免邻近正常组织受放射影响,从而减少副作用事件。质子束技术的引入及其在病理组织中能量具有最大范围的物理优势,有可能为前列腺癌患者避免膀胱和直肠等关键器官遭受影响。目前的数据局限于大的和观察性的研究,并且并没有阐释清楚质子治疗比IMRT传统治疗方法的优势。另外,质子束放射治疗的花费也增加了该治

放射技术的进展改变了局部前列腺癌患者的治疗选择。三维适形放射治疗和可调节强度放射治疗(IMRT)使得医生可以避免邻近正常组织受放射影响,从而减少副作用事件。质子束技术的引入及其在病理组织中能量具有最大范围的物理优势,有可能为前列腺癌患者避免膀胱和直肠等关键器官遭受影响。目前的数据局限于大的和观察性的研究,并且并没有阐释清楚质子治疗比IMRT传统治疗方法的优势。另外,质子束放射治疗的花费也增加了该治疗方法的争议。

最近,有研究人员进行了对所有的与前列腺癌相关的质子治疗进行了大量的文献调查。研究人员讨论了质子束技术的历史,以及在前列腺癌治疗中的角色,相关的矛盾,新技术驱使以及花费的讨论,以及现代大规模前瞻性研究总述。研究发现,与前列腺癌的标准治疗选择相比,质子束放射治疗是安全的和有效的。虽然剂量测定研究表明了质子治疗比光子治疗具有更低的全身辐射剂量以及理论上相对更高的生物学效应,还没有研究详细的阐释质子治疗的益处。

最后,研究人员指出,质子治疗的传输以及质子中心商务模式的发展趋势有助于减少花费。现存技术引入质子传输可以实现对器官运动进一步的控制并处理患病器官。另外,比较光子和质子治疗的研究并且包括患者报道的生活质量结果将会帮助人们理解质子和光子治疗在前列腺癌中的差异。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791574, encodeId=48b61e915742b, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 15 19:52:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364478, encodeId=884013644e824, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602149, encodeId=742b160214944, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630252, encodeId=4b5f163025218, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040440, encodeId=6b01104044016, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Apr 23 16:52:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791574, encodeId=48b61e915742b, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 15 19:52:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364478, encodeId=884013644e824, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602149, encodeId=742b160214944, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630252, encodeId=4b5f163025218, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040440, encodeId=6b01104044016, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Apr 23 16:52:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-25 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791574, encodeId=48b61e915742b, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 15 19:52:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364478, encodeId=884013644e824, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602149, encodeId=742b160214944, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630252, encodeId=4b5f163025218, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040440, encodeId=6b01104044016, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Apr 23 16:52:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-25 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791574, encodeId=48b61e915742b, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 15 19:52:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364478, encodeId=884013644e824, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602149, encodeId=742b160214944, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630252, encodeId=4b5f163025218, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040440, encodeId=6b01104044016, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Apr 23 16:52:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791574, encodeId=48b61e915742b, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Mon Jul 15 19:52:00 CST 2019, time=2019-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364478, encodeId=884013644e824, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602149, encodeId=742b160214944, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630252, encodeId=4b5f163025218, content=<a href='/topic/show?id=7d2764661f6' target=_blank style='color:#2F92EE;'>#治疗比较#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64661, encryptionId=7d2764661f6, topicName=治疗比较)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbf021471003, createdName=zhangyxzsh, createdTime=Thu Apr 25 04:52:00 CST 2019, time=2019-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040440, encodeId=6b01104044016, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Apr 23 16:52:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-23 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Lancet oncol:ADT疗法联合醋酸阿比特龙和强的松明显高危型转移性前列腺癌患者的总体存活期

LATTUDE研究的中期分析显示,雄激素阻断疗法(ADT)加上醋酸阿比特龙和强的松可明显提高新确诊的、对去雄敏感的、高危型前列腺癌(mCSPC)患者的总体存活率和无进展存活期。现研究人员对LATITUDE研究的长期存活效益和安全性进行最终的分析。LATTUDE研究是一个在34个国家的235个地点开展的多中心的、随机的、双盲III期试验,招募年满18岁的新确诊的、组织或细胞病理证实的前列腺转移癌患者

Sci Rep:机器人辅助腹腔镜前列腺癌根治术中异丙酚对炎症反应的作用研究

机器人辅助的腹腔镜前列腺癌根治术(RALRP)是一种微创手术;然而,一些外科手术创伤仍旧能够激发系统炎症。更多的是,RALRP期间的腹腔集气能够诱导再灌注损伤(IRI)。异丙酚是一种麻醉剂,且已知其具有抗炎症和抗氧化的特性。最近,有研究人员比较了异丙酚与地氟醚在RALRP中的炎症和IRI中的作用,具体是通过测量不同的生物标记和围手术期肾功能评估来比较的。研究包括了50名接受地氟醚(n=25)或者异

J Med Chem:研发出克服前列腺癌临床耐药的新型RORγ抑制剂

在本项工作中,研究团队利用片段组合及基于蛋白结构的优化策略,针对前期获得的前列腺癌新靶标RORγ发展了一种新型抑制剂XY101。该化合物显着抑制RORγ的转录活性(IC50 = 30 nM),具有优越的选择性、良好的代谢稳定性和体内生物利用度(T1/2 = 7.32 h, F = 59%)。在体外,化合物XY101可以抑制多种前列腺癌细胞的增殖与克隆形成,同时可有效抑制前列腺癌细胞中AR、AR-v

Oncogene:FDPS能与PTEN功能丧失协作促进前列腺癌恶化

法尼基焦磷酸合酶(FDPS)是一种甲羟戊酸途径酶,在一些癌症中高度表达,其中也包括了前列腺癌(PCa)。到目前为止,癌症中FDPS的机制、功能和临床意义仍旧还未探索。最近,有研究人员在PTEN功能缺陷和正常的人类和小鼠PCa细胞和肿瘤中评估了FDPS的表达以及其与癌症相关的表型。研究发现,FDPS的过表达与PTEN缺失在PTEN条件性敲除小鼠(P<0.05)中表现出协同作用(P<0.0

Eur Urol:重点治疗后机器人辅助的根治性前列腺切除术的效果研究

那些经历重点治疗(FT)后的前列腺癌(PC)局部复发患者,进行根治性前列腺切除术(RP)后的结果和毒性情况的相关研究很少。最近,有研究人员对进行抢救性机器人协助RP(S-RALP)的患者的围手术期,肿瘤和功能结果情况进行了鉴定,并确定了S-RALP失败的风险因素。研究是一个多中心的群体研究,包括了82名在FT后经历S-RALP的患者。所有的参与者均具有组织学确定的PC复发。研究发现,无进展生存在术

Sci Rep:前列腺癌细胞的高通量、时间分别率力学表型分析

世界范围内,前列腺癌是仅次于肺癌的男性诊断疾病。甚至是最好的诊断标准仍旧缺乏精度,导致组织检测的假阳性从而导致患者接受不必要的外科手术干预。明确的早期诊断工具的缺乏是一个很明显的问题。最近,有研究人员呈现了微流体平台,时间分辨流体力学拉伸器(TR-HS),该设备可以允许每秒内对上千个细胞的非破坏性应力进行动态的力学响应调查。TR-HS整合了高速成像和计算机视觉,从而实现悬浮于液体中单个细胞的自动化